#Canada #Vancouver #DPX Technology #BioVaxys Technology #Biovaxys Shares

BioVaxys Technology Corp. Completes Second Tranche of Private Placement

BioVaxys Technology Corp., a clinical-stage biopharmaceutical firm headquartered in Vancouver, BC, has recently concluded the second tranche of its private placement, raising a total of $175,000. This funding comes at a crucial time for the company as it pursues its mission to develop cancer and infectious disease treatments using innovative immunotherapies.

Details of the Private Placement

The second tranche saw BioVaxys issue 3,500,000 units, each priced at $0.05. Each unit comprises one common share and one warrant, which allows for the purchase of an additional share at $0.15 until December 18, 2026. This dual structure allows investors to not only participate in the current share offerings but also benefit from potential future growth of the company.

The funds raised will primarily be utilized for working capital, underscoring BioVaxys's commitment to efficiently managing its financial resources to support ongoing research and development.

The completion of this second tranche is significant as it follows a previous successful funding round, which reflects increasing investor confidence in BioVaxys's innovative approaches to immunotherapy. Notably, no finder's fees were incurred during this transaction, indicating a streamlined process facilitated directly by the company.

A Look at BioVaxys’s Mission

BioVaxys Technology Corp. stands at the forefront of developing therapies that target cancer, infectious diseases, and immunological disorders. Utilizing their proprietary DPX™ immune-educating technology platform, the company integrates various bioactive agents to foster long-lasting immune responses. The innovative DPX platform has shown promising results in pre-clinical and clinical trials, demonstrating its effectiveness in triggering robust T and B cell immune responses.

BioVaxys’s recent advancements aim not only to provide new treatment options for severe medical conditions but also to enhance patient quality of life through their unique approach to immunotherapy. Their focus on neoantigen-targeted treatments is a testament to their dedication to advancing cancer treatment methodologies.

BioVaxys’s commitment to transparency is reflected in this announcement, as the company notifies shareholders that all securities linked to the second tranche are subject to a statutory hold period until April 19, 2025. This measure ensures adherence to applicable securities legislation while providing potential investors with clarity regarding their investments.

Future Prospects

Looking forward, BioVaxys is focused on leveraging the funds raised through this private placement to accelerate its development pipeline. By continuing to drive innovation within the biopharmaceutical sector, the company aims to expand its range of treatments based on the DPX technology platform, especially in the realms of oncology and infectious diseases. The ability to attract capital through private placements is critical for sustaining research efforts and facilitating clinical trials, which can lead to groundbreaking therapies.

With its shares listed on the Canadian Securities Exchange and quoted on the Frankfurt Bourse, BioVaxys is positioning itself as a competitive player in the biotechnological landscape. As the company continues to build upon its successes, it strives for advancements that resonate with the urgent healthcare needs of today.

For additional insights into BioVaxys Technology Corp.'s mission, shareholders and interested parties are encouraged to visit www.biovaxys.com and engage with the company on social platforms like LinkedIn and X.

This update not only highlights the financial growth of BioVaxys Technology Corp. but also reinforces its commitment to revolutionizing the treatment landscape for serious medical conditions, setting the stage for their future endeavors in the biopharmaceutical field.